![HBV](https://www.adcreviews.com/wp-content/uploads/2022/11/HBV-240x144.jpg)
Development of hepatitis B virus inhibitor AB-836 terminated due to safety concerns
AB-836, a next-generation oral hepatitis B virus (HBV) capsid inhibitor (class II capsid inhibitor) that Arbutus Biopharma is developing for the treatment of chronic hepatitis